肥胖合并慢性呼吸衰竭的无创通气:双水平压力是否总优于单水平?
本文综述肥胖相关呼吸衰竭的临床表型(重度OSA、孤立性夜间低通气、OSA合并COPD)及PAP治疗证据。现有数据支持PAP改善呼吸衰竭、生活质量、医疗利用与死亡率;CPAP与NIV均安全有效,证据不支持对所有患者统一选择单一疗法,孤立性夜间低通气目前推荐NIV。
要点
- 肥胖相关呼吸衰竭存在多种表型,高碳酸血症与不良结局相关。
- CPAP与NIV在肥胖相关呼吸衰竭合并OSA(伴或不伴COPD)中均安全有效。
- 孤立性夜间低通气无CPAP研究,当前推荐NIV;需滴定并据再评估升降阶梯。
核心结论
- 现有数据支持PAP治疗改善肥胖相关呼吸衰竭,并与健康相关生活质量改善、医疗利用减少和死亡率降低相关。
- CPAP与NIV在肥胖相关呼吸衰竭合并OSA、伴或不伴COPD的患者中均安全有效,当前证据不支持对所有患者统一选择单一疗法。
- 孤立性夜间低通气患者缺乏CPAP研究,当前推荐NIV。
研究设计与样本
- 综述类文章,总结肥胖相关呼吸衰竭的临床表型与PAP治疗证据,并指出长期临床疗效试验较少。
主要发现
- 报告的表型包括重度阻塞性睡眠呼吸暂停(OSA)、伴或不伴重度OSA的孤立性夜间低通气、以及OSA合并慢性阻塞性肺疾病(COPD)。
- 高碳酸血症性呼吸衰竭的存在与上述各组患者的不良临床结局相关。
- 减重是管理核心目标但常难以实现,PAP治疗睡眠呼吸障碍是临床实践的主要手段。
- 缺乏 untreated 对照组的原因是缺乏临床均势。
关键数值与推荐
- 减重是管理核心目标但常难以实现。
- PAP治疗用于改善呼吸衰竭,并与健康相关生活质量改善、医疗利用减少和死亡率降低相关。
- 无论起始选用何种治疗,均应滴定以纠正睡眠呼吸障碍并逆转慢性呼吸衰竭,并基于临床再评估考虑降阶梯;未达到生理与临床治疗目标时应考虑升阶梯。
临床怎么用
- 对肥胖相关呼吸衰竭合并OSA(伴或不伴COPD)患者,CPAP或NIV均可选用,不统一指定单一疗法。
- 对孤立性夜间低通气患者,当前推荐NIV。
- 治疗需滴定至纠正睡眠呼吸障碍并逆转慢性呼吸衰竭,依据再评估进行升阶梯或降阶梯。
局限性
- 长期临床疗效试验较少。
- 缺乏临床均势使 untreated 对照组难以设置。
- 孤立性夜间低通气患者缺乏CPAP研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity-related respiratory failure is increasingly common but remains under-diagnosed and under-treated. There are several clinical phenotypes reported, including severe obstructive sleep apnoea (OSA), isolated nocturnal hypoventilation with or without severe OSA and OSA complicating chronic obstructive pulmonary disease (COPD). The presence of hypercapnic respiratory failure is associated with poor clinical outcomes in each of these groups. While weight loss is a core aim of management, this is often unachievable, and treatment of sleep-disordered breathing with positive airway pressure (PAP) therapy is the mainstay of clinical practice. Although there are few long-term clinical efficacy trials, the lack of equipoise would prevent the utilization of an untreated control group. The current data support the use of PAP therapy to improve respiratory failure and is associated with improvements in health-related quality of life, reduced healthcare utilization and reduced mortality. Both continuous PAP (CPAP) and non-invasive ventilation (NIV) appear safe and effective in patients with obesity-related respiratory failure and OSA, with or without COPD, and the current evidence would not support a single therapy choice in all patients. There are no studies of CPAP in patients with isolated nocturnal hypoventilation, and NIV would be the current recommendation in this patient group. Whichever starting therapy is used, titration should be performed to correct sleep-disordered breathing and reverse chronic respiratory failure, with consideration of step-down of the treatment based on a clinical re-evaluation. In contrast, failure to reach physiological and clinical treatment targets should lead to the consideration of treatment escalation.
引用
- Murphy PB, Suh ES, Hart N, et al. Non-invasive ventilation for obese patients with chronic respiratory failure: Are two pressures always better than one? Respirology. 2019. PMID: 31121638. doi:10.1111/resp.13588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。